Form 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

  [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the quarterly period ended March 31, 2014.

 

Or

 

  [  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the transition period from ___________ to ___________

 

Commission File Number 000-53071

 

TARGETED MEDICAL PHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   20-5863618
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

2980 Beverly Glen Circle, Los Angeles, California   90077
(Address of principal executive offices)   (Zip Code)

 

(310) 474-9809

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ] Non-accelerated filer [  ] Smaller reporting company [X]
    (Do not check if a smaller reporting company)  

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

Shares outstanding of the Registrant’s common stock:

 

Class   Outstanding as of May 13, 2014
Common stock, $0.001 par value   26,422,847

 

 

 

 
 

 

TARGETED MEDICAL PHARMA, INC.

 

FORM 10-Q FOR THE QUARTER

ENDED MARCH 31, 2014

 

TABLE OF CONTENTS

 

    Page
PART I – FINANCIAL INFORMATION  
   
ITEM 1. Financial Statements 3
  Condensed Consolidated Balance Sheets 3
  Condensed Consolidated Statements of Operations 4
  Condensed Consolidated Statements of Cash Flows 5
  Notes to Condensed Consolidated Financial Statements 6
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 29
ITEM 4. Controls and Procedures 29
   
PART II – OTHER INFORMATION  
     
ITEM 1. Legal Proceedings 30
ITEM 1A. Risk Factors 30
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 30
ITEM 3. Defaults Upon Senior Securities 30
ITEM 4. Mine Safety Disclosures 30
ITEM 5. Other Information 30
ITEM 6. Exhibits 30
   
SIGNATURES 31

 

2
 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

 

Condensed Consolidated Balance Sheets (Unaudited)            
         
    March 31, 2014     December 31, 2013  
ASSETS                
                 
CURRENT ASSETS                
                 
Cash   $ 92,586     $ 491,806  
Accounts receivable, net     362,357       268,834  
Inventories     478,645       595,753  
Prepaid income taxes     900,863       900,863  
Other current assets     481,280       372,262  
TOTAL CURRENT ASSETS     2,315,731       2,629,518  
                 
Property and equipment, net     203,003       235,586  
Intangible assets, net     2,061,116       2,132,649  
TOTAL ASSETS   $ 4,579,850     $ 4,997,753  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                 
CURRENT LIABILITIES                
                 
Accounts payable   $ 1,539,020     $ 1,497,425  
Accrued liabilities     6,143,509       5,654,682  
Notes payable, current portion - related parties     2,466,887       2,621,067  
Notes payable, current portion     1,544,470       1,458,315  
Derivative liability     33,617       29,134  
TOTAL CURRENT LIABILITIES     11,727,503       11,260,623  
                 
Notes payable, less current portion, net     376,264       754,828  
TOTAL LIABILITIES     12,103,767       12,015,451  
                 
COMMITMENTS AND CONTINGENCIES (SEE NOTE 10)                
                 
STOCKHOLDERS’ DEFICIT                
                 
Preferred stock, $0.001 par value: 20,000,000 shares authorized; no shares issued and outstanding                
Common stock, $0.001 par value: 100,000,000 shares authorized; 26,422,847 shares issued and outstanding as of March 31, 2014; 25,741,181 shares issued and outstanding as of December 31, 2013     26,423       25,741  
Additional paid-in capital     16,446,537       15,978,968  
Accumulated deficit     (23,996,877 )     (23,022,407 )
TOTAL STOCKHOLDERS’ DEFICIT     (7,523,917 )     (7,017,698 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT   $ 4,579,850     $ 4,997,753  

 

The accompanying notes are an integral part of these financial statements.

 

3
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

 

Condensed Consolidated Statements of Operations (Unaudited)    
     
   Three Months Ended March 31, 
   2014   2013 
         
REVENUES          
Product revenue  $1,633,280   $2,479,551 
Service revenue   167,623    331,580 
Total revenue   1,800,903    2,811,131 
           
COST OF SALES          
Cost of product sold   139,319    351,479 
Cost of services sold   420,215    547,195 
Total cost of sales   559,534    898,674 
           
Gross profit   1,241,369    1,912,457 
           
OPERATING EXPENSES          
Research and development   58,483    32,080 
Selling, general and administrative   1,893,672    2,388,638 
Total operating expenses   1,952,155    2,420,718 
           
Loss from operations   (710,786)   (508,261)
           
OTHER INCOME (EXPENSES)          
Interest income (expense)   (259,200)   (89,518)
Change in fair value of warrant liability   (4,484)   87,979 
Total other income (expenses)   (263,684)   (1,539)
           
Loss before income taxes   (974,470)   (509,800)
           
Income tax benefit       (239,523)
           
NET LOSS  $(974,470)  $(270,277)
           
Basic and diluted net loss per common share  $(0.04)  $(0.01)
           
Basic and diluted weighted average common shares outstanding   25,902,551    23,010,015 

 

The accompanying notes are an integral part of these financial statements.

 

4
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

 

Condensed Consolidated Statements of Cash Flows (Unaudited)        
         
   Three Months Ended March 31, 
   2014   2013 
Cash flows from operating activities:          
Net loss  $(974,470)  $(270,277)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   32,583    35,377 
Amortization   72,413    65,178 
Amortization of debt discount   115,690    28,189 
Stock-based compensation to employees and directors   12,451    291,178 
Stock-based compensation to consultants   215,800     
Deferred income tax benefit       (239,523)
Change in fair value of warrant derivative liability   4,483    (87,979)
Changes in operating assets and liabilities:          
Accounts receivable   (93,523)   (165,865)
Loan receivables - employees       681 
Inventories   117,108    (215,979)
Other current assets   (109,018)   (103,522)
Accounts payable   41,595    82,247 
Accrued liabilities   488,827    605,023 
           
Net cash (used) provided by operating activities   (76,061)   24,728 
           
Cash flows from investing activities:          
Acquisition of intangible assets   (880)   (57,187)
Purchase of property and equipment       (11,208)
           
Net cash used by investing activities   (880)   (68,395)
           
Cash flows from financing activities:          
Proceeds from issuance of common stock   240,000     
Payments and decrease on notes payable - related parties   (154,180)   (225,000)
Payments and decrease on notes payable   (408,099)    
           
Net cash used by financing activities   (322,279)   (225,000)
           
Net decrease in cash   (399,220)   (268,667)
           
Cash at beginning of period   491,806    326,603 
           
Cash at end of period  $92,586   $57,936 
           
Supplemental disclosures of cash flow information:          
Cash paid during the period for interest  $142,934   $210,474 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

5
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited

  

1. DESCRIPTION OF BUSINESS

 

Targeted Medical Pharma, Inc. (the “Company” or “TMP”), also doing business as Physician Therapeutics (“PTL”), is a specialty pharmaceutical company that develops and commercializes nutrient and pharmaceutical based therapeutic systems. On July 30, 2007, the Company formed Complete Claims Processing, Inc. (“CCPI”), a wholly owned subsidiary which provides billing and collection services on behalf of physicians for claims to insurance companies, governmental agencies, and other medical payers.

 

Segment Information:

 

The Company did not recognize revenue outside of the United States during the three months ended March 31, 2014 and 2013. The Company’s operations are organized into two reportable segments: TMP and CCPI.

 

TMP: This segment includes PTL. TMP develops and distributes nutrient based therapeutic products and distributes pharmaceutical products from other manufacturers through employed sales representatives and distributors. TMP also performs the administrative, regulatory compliance, sales and marketing functions of the corporation, owns the corporation’s intellectual property, is responsible for research and development relating to medical food products and development of software used for the dispensation and billing of medical foods, generic and branded products. The TMP segment also manages contracts and chargebacks.

 

CCPI: This segment provides point-of-care dispensing solutions and billing and collections services.

 

Results for the three months ended March 31, 2014 and 2013, are reflected in the table below:

 

For the three months ended March 31,

 

2014 (Unaudited)  Total   TMP   CCPI 
Gross sales  $1,800,903   $1,633,280   $167,623 
Gross profit  $1,241,369   $1,493,961   $(252,592)
Net loss  $(974,470)  $(721,878)  $(252,592)
Total assets  $4,579,850   $4,540,622   $39,228 
                
2013 (Unaudited)               
Gross sales  $2,811,131   $2,479,551   $331,580 
Gross profit  $1,912,457   $2,128,072   $(215,615)
Net loss  $(270,277)  $(54,662)  $(215,615)
Total assets  $12,224,838   $12,164,138   $60,700 

 

2. LIQUIDITY AND GOING CONCERN

 

The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company reported losses for the three months ended March 31, 2014, totaling $974,470 as well as an accumulated deficit as of March 31, 2014, amounting to $23,996,877. Contributing to the accumulated deficit was the Company’s decision to maintain a full valuation allowance for its net deferred tax assets. At March 31, 2014, the existence of a full valuation allowance represented $7,682,867 of the Company’s accumulated deficit. Further, the Company does not have adequate cash to cover projected operating costs for the next 12 months. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In order to ensure the continued viability of the Company, either future equity financings must be obtained or profitable operations must be achieved in order to repay the existing short-term debt and to provide a sufficient source of operating capital. No assurances can be made that the Company will be successful obtaining the equity financing needed to continue to fund its operations, or that the Company will achieve profitable operations and positive cash flow. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

6
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

3. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Regulation S-X and do not include all the information and disclosures required by accounting principles generally accepted in the United States of America. The Company has made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. The actual results experienced by the Company may differ materially from our estimates. The consolidated financial information is unaudited but reflects all normal adjustments that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods presented. The consolidated balance sheet as of December 31, 2013 was derived from the Company’s audited financial statements. The consolidated financial statements should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Results of the three months ended March 31, 2014, are not necessarily indicative of the results to be expected for the full year ending December 31, 2014.

 

Principles of Consolidation

 

The consolidated financial statements include accounts of TMP and its wholly owned subsidiary, CCPI (collectively referred to as “the Company”). All significant intercompany accounts and transactions have been eliminated in consolidation. In addition, TMP and CCPI share the common operating facility, certain employees and various costs. Such expenses are principally paid by TMP. Due to the nature of the parent and subsidiary relationship, the individual financial position and operating results of TMP and CCPI may be different from those that would have been obtained if they were autonomous.

 

Cash Equivalents

 

The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less when purchased to be cash equivalents. The recorded carrying amounts of the Company’s cash and cash equivalents approximate their fair market value. As of March 31, 2014 and 2013, the Company had no cash equivalents.

  

Accounting Estimates

 

The preparation of financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include revenue recognition, share based compensation, recoverability of intangibles, valuation of derivatives, and valuation of deferred income taxes. Actual results could differ from those estimates.

 

Revenue Recognition

 

TMP markets medical foods and generic and branded pharmaceuticals through employed sales representatives, independent distributors, and pharmacies. Product sales are invoiced upon shipment at Average Wholesale Price (“AWP”), which is a commonly used term in the industry, with varying rapid pay discounts, under six models: Physician Direct Sales, Distributor Direct Sales, Physician Managed, Hybrid Models, and two Cambridge Medical Funding Group Models.

 

7
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

Under the following revenue models, product sales are invoiced upon shipment:

 

Physician Direct Sales Model (2% of product revenues for the three months ended March 31, 2014): Under this model, a physician purchases products from TMP, but does not retain CCPI’s services. TMP invoices the physician upon shipment under terms which allow a significant rapid pay discount off AWP for payment within discount terms, in accordance with the product purchase agreement. The physicians dispense the product and perform their own claims processing and collections. TMP recognizes revenue under this model on the date of shipment at the gross invoice amount less the anticipated rapid pay discount offered in the product purchase agreement. In the event payment is not received within the term of the agreement, the amount due from the physician for the purchased TMP products reverts to the AWP. In addition, if payment is not received within the agreed-upon term, a late payment fee of up to 20% may be applied to the outstanding balance. The physician is responsible for payment directly to TMP.

 

Distributor Direct Sales Model (18% of product revenues for the three months ended March 31, 2014): Under this model, a distributor purchases products from TMP, sells those products to a physician, and the physician does not retain CCPI’s services. TMP invoices distributors upon shipment under terms which include a significant discount off AWP. TMP recognizes revenue under this model on the date of shipment at the net invoice amount. In the event payment is not received within the term of the agreement, the amount payable for the purchased TMP products reverts to the AWP. In addition, if payment is not received within the agreed-upon term, a late payment fee of up to 20% may be applied to the outstanding balance.

 

Physician Managed Model (33% of product revenues for the three months ended March 31, 2014): Under this model, a physician purchases products from TMP and retains CCPI’s services. TMP invoices the physician upon shipment under terms which allow a significant rapid pay discount for payment received within terms in accordance with the product purchase agreement, which includes a security interest for TMP in the products and receivables generated by the dispensing of the products. The physician also executes a billing and claims processing services agreement with CCPI for billing and collection services relating to our products (discussed below). CCPI submits a claim for reimbursement on behalf of the physician client. The CCPI fee and product invoice amount are deducted from the reimbursement received by CCPI on behalf of the physician client before the reimbursement is forwarded to the physician client. In the event the physician fails to pay the product invoice within the agreed term, we can deduct the payment due from any of the reimbursements received by us on behalf of the physician client as a result of the security interest we obtained in the products we sold to the physician client and the receivables generated by selling the products in accordance with our agreement. In the event payment is not received within the term of the agreement, the amount due from the physician for the purchased TMP products reverts to the AWP. In addition, if payment is not received within the agreed-upon term, a late payment fee of up to 20% may be applied to the outstanding balance.

 

Hybrid Model (8% of product revenues for the three months ended March 31, 2014): Under this model, a distributor purchases products from TMP and sells those products to a physician and the physician retains CCPI’s services. TMP invoices distributors upon shipment under terms which allow a significant rapid pay discount for payment received within terms in accordance with the product purchase agreements. The physician client of the distributor executes a billing and claims processing services agreement with CCPI for billing and collection services (discussed below). The distributor product invoice and the CCPI fee are deducted from the reimbursement received by CCPI on behalf of the physician client before the reimbursement is forwarded to the distributor for further delivery to their physician clients. In the event payment is not received within the term of the agreement, the amount payable for the purchased TMP products reverts to the AWP. In addition, if payment is not received within the agreed-upon term, a late payment fee of up to 20% may be applied to the outstanding balance.

 

Since we are in the early stage of our business, as a courtesy to our physician clients, our general practice has been to extend the rapid pay discount from our Physician Managed and Hybrid models beyond the initial term of the invoice until the invoice is paid and not to apply a late payment fee to the outstanding balance.

 

Due to substantial uncertainties as to the timing and collectability of revenues derived from our Physician Managed and Hybrid models, which can take in excess of five years to collect, we have determined that these revenues do not meet the criteria for recognition, in accordance with The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic No. ASC 605, Revenue Recognition (“ASC 605”), upon shipment. These revenues are recorded when collectability is reasonably assured, which the Company has determined is when the payment is received, which is upon collection of the claim.

 

8
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

The Company has entered into two separate agreements with Cambridge Medical Funding Group, LLC (“CMFG”) related to California Workers’ Compensation (“WC”) benefit claims. Under each arrangement, we have determined that pursuant to FASB ASC Topic No. 860, Transfers of Financial Assets and ASC 605 we have met the criteria for revenue recognition when payment is received, which is upon collection of the claim as described below.

 

CMFG #1 – WC Receivable Purchase Assignment Model (“CMFG #1”) (39% of product revenues for the three months ended March 31, 2014): Under this model, physicians who purchase products from TMP under the Company’s Physician Managed Model will have the option to assign their accounts receivables (primarily those accounts receivables with dates of service starting with the year 2013) from California WC benefit claims to CMFG at a discounted rate. Each agreement is executed among CMFG, TMP, and each individual physician, and serves as a master agreement for all assigned receivables by the physician to CMFG. Since these accounts receivable originated from the Company’s Physician Managed Model, CCPI’s services are also retained. The physician’s fees and financial obligations due to TMP, for the purchase of TMP product and use of CCPI’s services, are satisfied directly by CMFG, usually within seven (7) days of transmission of the accounts receivable to CMFG. CMFG has agreed to pay an amount equal to 23% of eligible assigned accounts receivable as an advance payment. CMFG makes this payment directly to TMP, on behalf of the physician. TMP applies this payment to the physician’s financial obligations due to CCPI for the physician’s use of the Company’s medical billing and claims processing services, and the physician’s financial obligation due to TMP for the cost of the product. The Company recognizes revenue on the date that payment is due from CMFG. Under CMFG #1, the Company only receives the 23% advance payment, where such payment is without recourse or future obligation for TMP to repay the 23% advanced amount back to CMFG or the physician. Actual amounts collected on the assigned accounts receivable are shared between CMFG and the physician, where the first 41% of amounts collected are disbursed to CMFG and additional amounts collected are shared at a ratio of 75:25, where 75% is disbursed to the physician and 25% is disbursed to CMFG.

 

CMFG #2 – WC Receivables Funding Assignment Model (“CMFG #2”): Under this model, the Company has assigned the future proceeds of accounts receivable of WC benefit claims with dates of service between the year 2007 and December 31, 2012, to CMFG. These accounts receivables were originally generated from either the Company’s Physician Managed Model or the Hybrid Model. Since these accounts receivable originated from the Company’s Physician Managed Model or the Hybrid Model, CCPI’s services are also retained. As further detailed at Note 7, CMFG paid the Company $3.2 million for such assignment, which is considered a loan to the Company from CMFG secured by the future proceeds of these receivables. As detailed in Note 7, actual amounts collected on the claims receivable is shared between CMFG and the Company based upon a predetermined schedule, until the $3.2 million secured loan is paid back to CMFG. Further collections are shared at a ratio of 55:45, where 55% is retained by the Company and 45% disbursed to CMFG. The Company recognizes revenue when payment is received from the insurance carriers or the California State Compensation Insurance Fund.

 

During the three months ended March 31, 2014 and 2013, the Company issued billings to Physician Managed and Hybrid model customers aggregating $0.9 million and $1.7 million, respectively, which were not recognized as revenues or accounts receivable in the accompanying consolidated financial statements at the time of such billings. Direct costs associated with the above billings are expensed as incurred. Direct costs associated with all billings, aggregating $139,319 and $351,479, respectively, were expensed in the accompanying consolidated financial statements at the time of such billings. In accordance with the Company’s revenue recognition policy, the Company recognized revenues from certain of these customers when cash was collected, aggregating $666,446 and $1,446,834 during the three months ended March 31, 2014 and 2013, respectively. The $666,446 of Physician Managed and Hybrid model revenue recognized during the three months ended March 31, 2014, includes $394,946 of cash received under CMFG #2. As of March 31, 2014, we had approximately $8.0 million in unrecorded accounts receivable that potentially will be recorded as revenue in the future as our CCPI subsidiary secures claims payments on behalf of our PMM and Hybrid Customers. All unpaid invoices underlying claims assigned to CMFG pursuant to CMFG #1 are excluded from unrecorded accounts receivable.

 

CCPI receives no revenue in the Physician Direct or Distributor Direct models because it does not provide collection and billing services to these customers. In the Physician Managed and Hybrid models, including CMFG #2, CCPI has a billing and claims processing service agreement with the physician. The billing and claims processing agreement includes a service fee that is based upon a percentage of collections on all claims. Because fees are only earned by CCPI upon collection of the claim, and the fee is not determinable until the amount of the collection of the claim is known, CCPI recognizes revenue at the time claims are paid. Under CMFG #1 the Company recognizes revenue related to CCPI’s services upon receipt of the 23% advance payment from CMFG.

 

9
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

No returns of products are allowed except for products damaged in shipment, which historically have been insignificant.

  

The rapid pay discounts to the AWP amount offered to the physician or distributor vary based upon the expected payment term from the physician or distributor. The discounts are derived from the Company’s historical experience of the collection rates from internal sources and updated for facts and circumstances and known trends and conditions in the industry, as appropriate. As described in the various models, we recognize provisions for rapid pay discounts in the same period in which the related revenue is recorded. We believe that our current provisions appropriately reflect our exposure for rapid pay discounts. These rapid pay discounts have typically ranged from 40% to 88% of AWP.

 

Allowance for Doubtful Accounts

 

Trade accounts receivable are stated at the amount management expects to collect from outstanding balances. Currently, accounts receivable are comprised of amounts due from our distributor customers and receivables from our PDRx equipment. The carrying amounts of accounts receivable are reduced by an allowance for doubtful accounts that reflects management’s best estimate of the amounts that will not be collected. The Company individually reviews all accounts receivable balances and based upon an assessment of current creditworthiness, estimates the portion, if any, of the balance that will not be collected. An allowance is recorded for those accounts that are determined to likely be uncollectible through a charge to earnings and a credit to a valuation allowance. Balances that are still outstanding after we have used reasonable collection efforts will be written off. Based on an assessment as of March 31, 2014, of the collectability of invoices, we established an allowance for doubtful accounts of $55,773.

 

Under the Company’s Physician Managed Model and Hybrid Model, CCPI performs billing and collection services on behalf of the physician client and deducts the CCPI fee and product invoice amount from the reimbursement received by CCPI on behalf of the physician client before the reimbursement is forwarded to the physician client. Extended collection periods are typical in the workers compensation industry with payment terms extending from 45 days to in excess of five years. The physician remains personally liable for purchases of product from TMP and TMP retains a security interest in all products sold to the physician, and the resulting claims receivable from sales of the products. CCPI maintains an accounting of all managed accounts receivable on behalf of the physician. As described above, due to uncertainties as to the timing and collectability of revenues derived from these models, revenue is recorded when payment is received, there is no related accounts receivable, and therefore no allowance for doubtful accounts is necessary.

 

Inventory Valuation

 

Inventory is valued at the lower of cost (first in, first out) or market and consists primarily of finished goods.

 

Property and Equipment

 

Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Computer equipment is depreciated over three to five years. Furniture and fixtures are depreciated over five to seven years. Leasehold improvements are amortized over the shorter of fifteen years or term of the applicable property lease. Maintenance and repairs are expensed as incurred; major renewals and betterments that extend the useful lives of property and equipment are capitalized. When property and equipment is sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized. Amenities are capitalized as leasehold improvements.

 

10
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

Impairment of Long-Lived Assets

 

The long-lived assets held and used by the Company are reviewed for impairment no less frequently than annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. No impairment indicators existed at December 31, 2013, or March 31, 2014, so no long-lived asset impairment was recorded for the year ended December 31, 2013, or the three months ended March 31, 2014.

 

Intangible Assets

 

Intangible assets with finite lives, including patents and internally developed software (primarily the Company’s PDRx Software), are stated at cost and are amortized over their useful lives. Patents are amortized on a straight line basis over their statutory lives, usually fifteen to twenty years. Internally developed software is amortized over three to five years. Intangible assets with indefinite lives are tested annually for impairment, during the fiscal fourth quarter and between annual periods, and more often when events indicate that an impairment may exist. If impairment indicators exist, the intangible assets are written down to fair value as required. The Company has one intangible asset with an indefinite life which is a domain name for medical foods. No impairment indicators existed at December 31, 2013, or March 31, 2014, so no intangible asset impairment was recorded for the year ended December 31, 2013, or the three months ended March 31, 2014.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments are accounts receivable, accounts payable, notes payable, and warrant derivative liability. The recorded values of accounts receivable and accounts payable approximate their values based on their short term nature. Notes payable are recorded at their issue value or if warrants are attached at their issue value less the value of the warrant. Warrants issued with ratcheting provisions are revalued using the Black-Scholes model each quarter based on changes in the market value of our common stock and unobservable level 3 inputs.

 

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase common stock.

 

Derivative Financial Instruments

 

Derivative liabilities are recognized in the consolidated balance sheets at fair value based on the criteria specified in FASB ASC Topic 815-40 Derivatives and Hedging – Contracts in Entity’s own Equity (“ASC 815-40”). Pursuant to ASC 815-40, an evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as a derivative liability instead of as equity. The estimated fair value of warrants classified as derivative liabilities is determined using the Black-Scholes option pricing model. The model utilizes Level 3 unobservable inputs to calculate the fair value of the warrants at each reporting period. The Company determined that using an alternative valuation model such as a Binomial-Lattice model would result in minimal differences. The fair value of warrants classified as derivative liabilities is adjusted for changes in fair value at each reporting period, and the corresponding non-cash gain or loss is recorded as other income or expense in the consolidated statement of operations. As of March 31, 2014, 95,000 warrants were classified as derivative liabilities. Each reporting period the warrants are re-valued and adjusted through the caption “change in fair value of warrant liability” on the consolidated statements of operations. The Company’s remaining warrants are recorded to additional paid in capital as equity instruments.

 

11
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

Income Taxes

 

The Company determines its income taxes under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities. Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related asset or liability. Those not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized.

 

The Company recognizes tax liabilities by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters is different than the amount recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities. Management of the Company has evaluated tax positions taken by the Company and has concluded that as of March 31, 2014, there are no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require disclosure in the financial statements.

 

The Company’s effective tax rates were approximately 0% and 47% for the three months ended March 31, 2014 and 2013, respectively.  During the three months ended March 31, 2014, the effective tax rate differed from the U.S. federal statutory rate primarily due to the change in the valuation allowance. In the previous year, management had decided to fully reserve the net deferred income tax assets by taking a full valuation allowance against these assets. During the three months ended March 31, 2013, the effective tax rate differed primarily due to the effect of changes in the fair value of the Company’s warrant derivative liability.

 

During the quarter ended June 30, 2013, the Company decided to fully reserve the net deferred income tax assets by taking a full valuation allowance against these assets. As a result of this decision, during the three months ended March 31, 2014, the Company did not recognize any income tax expense. The table below shows the balances for the deferred income tax assets and liabilities as of the dates indicated.

 

   March 31, 2014   December 31, 2013 
Deferred income tax asset-short-term  $1,431,178   $1,402,031 
Allowance   (1,431,178)   (1,402,031)
Deferred income tax asset-short-term, net        
           
Deferred income tax asset-long-term   7,317,600    7,145,404 
Deferred income tax liability-long-term   (1,065,911)   (1,177,716)
Deferred income tax asset-long-term   6,251,689    5,967,688 
Allowance   (6,251,689)   (5,967,688)
Deferred income tax asset-long-term, net        
           
Total deferred tax asset, net        

 

The ultimate realization of deferred tax assets is dependent upon the existence, or generation, of taxable income in the periods when those temporary differences and net operating loss carryovers are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in carryover years, projected future taxable income, available tax planning strategies, and other factors in making this assessment. Based on available evidence, management believes it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company has maintained a valuation allowance for the current year.

 

12
 
 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

At March 31, 2014, the Company had total domestic Federal and state net operating loss carryovers of approximately $5,957,000 and $8,757,000, respectively. Federal and state net operating loss carryovers expire at various dates between 2024 and 2032.

 

Under the Tax Reform Act of 1986, as amended, the amounts of and benefits from net operating loss carryovers and research and development credits may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50%, as defined, over a three year period. The Company does not believe that such an ownership change has occurred.

 

Stock-Based Compensation

 

The Company accounts for stock option awards in accordance with FASB ASC Topic No. 718, Compensation-Stock Compensation. Under FASB ASC Topic No. 718, compensation expense related to stock-based payments is recorded over the requisite service period based on the grant date fair value of the awards. Compensation previously recorded for unvested stock options that are forfeited is reversed upon forfeiture. The Company uses the Black-Scholes option pricing model for determining the estimated fair value for stock-based awards. The Black-Scholes model requires the use of assumptions which determine the fair value of stock-based awards, including the option’s expected term and the price volatility of the underlying stock.

 

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of FASB ASC Topic No. 505-50, Equity Based Payments to Non-Employees. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.

 

Loss per Common Share

 

The Company utilizes FASB ASC Topic No. 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible debentures, options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity.

 

Since the effects of outstanding options, warrants, and the conversion of convertible debt are anti-dilutive in all periods presented, shares of common stock underlying these instruments have been excluded from the computation of loss per common share.

 

13
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of March 31, 2014 and 2013:

 

   March 31, 
   2014   2013 
Warrants   4,256,465    2,423,965 
Stock options   2,424,241    2,125,741 
Convertible promissory notes       287,648 
    6,680,706    4,837,354 

 

Research and Development

 

Research and development costs are expensed as incurred. In instances where we enter into agreements with third parties for research and development activities, we may prepay fees for services at the initiation of the contract. We record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Typically, we expense 50% of the contract amount within the first two years of the contract and 50% over the remainder of the record retention requirements under the contract based on our experience on how long the clinical trial service is provided.

 

Reclassifications

 

Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations.

 

Recent Accounting Pronouncements

 

In February 2013, the FASB issued guidance on disclosure requirements for items reclassified out of accumulated other comprehensive income. This new guidance requires entities to present (either on the face of the statement of operations or in the notes to the financial statements) the effects on the line items in the statement of operations for amounts reclassified out of accumulated other comprehensive income. The new guidance was effective for us beginning in the first quarter of fiscal 2014. The adoption of the guidance did not impact our financial statement presentation and/or our disclosures, our financial position, results of operations or cash flows.

 

4. STOCK-BASED COMPENSATION

In January 2011 the Company’s stockholders approved the Company’s 2011 Stock Incentive Plan (the “Plan”), which provided for the issuance of a maximum of three million (3,000,000) shares of the Company’s common stock to be offered to the Company’s directors, officers, employees, and consultants. On August 26, 2013, subject to stockholder approval, the Company’s Board of Directors approved a two million (2,000,000) share increase in the number of shares issuable under the Plan. Options granted under the Plan have an exercise price equal to or greater than the fair market value of the underlying common stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between 5 and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.

 

During the three months ended March 31, 2014, the Company had stock-based compensation expense of $12,451 related to issuances to the Company’s employees and directors, included in reported net loss. The total amount of stock-based compensation for the three months ended March 31, 2014, related solely to the issuance of stock options. During the three months ended March 31, 2013, the Company had stock-based compensation expense included in reported net loss of $291,178. The total amount of stock-based compensation for the three months ended March 31, 2013, of $291,178, included restricted stock grants valued at $6,540 and stock options valued at $284,638.

 

14
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES CONDENSED TO CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

A summary of stock option activity for the three months ended March 31, 2014, is presented below:

 

       Outstanding Options 
   Shares Available for Grant   Number of Shares   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life (years)   Aggregate Intrinsic Value 
                     
December 31, 2012   865,556    1,770,437   $2.31    8.10   $1,113,383 
Amendment of 2011 SIP   2,000,000                    
Grants   (1,198,300)   1,198,300   $1.28           
Cancellations and forfeitures   173,896    (173,896)  $2.01           
Restricted stock awards   (123,455)                   
                          
December 31, 2013   1,717,697    2,794,841   $1.89    7.03   $ 
Cancellations and forfeitures   370,600    (370,600)  $2.63           
                          
March 31, 2014   2,088,297    2,424,241   $1.77    6.63   $19,255 

 

The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between our closing stock price on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. There have not been any options exercised during either the three months ended March 31, 2014 or the year ended December 31, 2013.

 

All options that the Company granted during the three months ended March 31, 2014 and 2013, were granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the issuance of these financial statements, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of our common stock from our authorized shares instead of settling such obligations with cash payments.

 

The Company utilized the Black-Scholes option pricing model. The Company did not issue any options during the three months ended March 31, 2014. The assumptions used for the three months ended March 31, 2013 are as follows:

 

   March 31, 2013 
Weighted average risk free interest rate  0.51% - 0.85% 
Weighted average life (in years)  3.5 - 5.0 
Volatility  87%
Expected dividend yield  0%
Weighted average grant-date fair value per share of options granted  $0.92 

 

15
 

 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

A summary of the changes in the Company’s nonvested options during the three months ended March 31, 2014, is as follows:

 

    Number of Non-vested Options   Weighted Average Fair Value at Grant Date   Intrinsic Value 
              
Non-vested at December 31, 2013    250,000   $0.60     
Vested in 3 months ended March 31, 2014    25,000   $0.93     
Non-vested at March 31, 2014    225,000   $0.56     
Exercisable at March 31, 2014    2,199,241   $0.94   $19,255 
Outstanding at March 31, 2014    2,424,241   $0.91   $19,255 

 

As of March 31, 2014, total unrecognized compensation cost related to unvested stock options was $111,031. The cost is expected to be recognized over a weighted average period of 2.69 years.

 

5. WARRANTS

 

Between May 2013 and December 31, 2013, a total of 1,832,500 warrants, at an average exercise price of $2.01 per share, were issued. Included in this amount are 1,412,500 warrants issued to James Giordano, CEO of CMFG, and 400,000 to Raven Asset-Based Opportunity Fund I LP, in connection with the June 28, 2013 loan to the Company by CMFG (See Note 7). The warrants were valued using the Black-Scholes valuation model assuming expected dividend yield, risk-free interest rate, expected life and volatility of 0%, 0.75% – 2.66%, five to ten years and 70.82% – 86.35%, respectively.

 

The following table summarizes information about common stock warrants outstanding at March 31, 2014:

 

Outstanding   Exercisable 
        Weighted             
        Average   Weighted       Weighted 
        Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Price   Outstanding   Life (Years)   Price   Exercisable   Price 
$1.00    1,710,000    3.24   $1.00    1,710,000   $1.00 
$2.00    1,812,500    9.30   $2.00    1,412,500   $2.00 
$2.60    20,000    4.10   $2.60    20,000   $2.60 
$3.38    713,965    2.82   $3.38    713,965   $3.38 
                           
$1.00 - 3.38    4,256,465    5.75   $1.83    3,856,465   $1.82 

 

Included in the Company’s outstanding warrants are 2,423,964 warrants that were issued to a related party over the period from August 2011 through July 2012 at exercise prices ranging from $1.00 to $3.38. One of the related party warrants contains provisions that require it to be accounted for as a derivative security. As of March 31, 2014, and December 31, 2013, the value of the related liability was $33,617 and $29,133, respectively. Changes in these values are recorded as income or expense during the reporting period that the change occurs.

 

16
 
 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

6. ACCRUED LIABILITIES

 

Accrued liabilities at March 31, 2014, and December 31, 2013, are comprised of the following:

 

   March 31, 2014   December 31, 2013 
         
Due to physicians  $2,922,582   $2,580,855 
Accrued salaries and director fees   2,745,070    2,567,847 
Other   475,857    505,980 
Total accrued liabilities  $6,143,509   $5,654,682 

 

7. NOTES PAYABLE

 

Notes payable at March 31, 2014, and December 31, 2013, are comprised of the following:

 

   March 31, 2014   December 31, 2013 
Notes payable to William Shell Survivor’s Trust (a)  $1,902,956   $2,007,820 
Notes payable to Giffoni Family Trust (b)   63,931    113,247 
Notes payable to Lisa Liebman (c)   500,000    500,000 
Note payable to Cambridge Medical Funding Group, LLC (d)   2,499,185    2,907,284 
Total notes payable   4,966,072    5,528,351 
Less: debt discount   (578,451)   (694,141)
    4,387,621    4,834,210 
Less: current portion   (4,011,357)   (4,079,382)
Notes payable – long-term portion  $376,264   $754,828 

 

(a)Between January 2011 and December 2012, William E. Shell, M.D., the Company’s Chief Executive Officer, Chief Scientific Officer, greater than 10% shareholder and a director, loaned $5,132,334 to the Company. As consideration for the loans, the Company issued promissory notes in the aggregate principal amount of (i) $4,982,334 to the Elizabeth Charuvastra and William Shell Family Trust dated July 27, 2006 and amended September 29, 2006 (the “Family Trust”), and (ii) $150,000 to the William Shell Survivor’s Trust (the “Survivor’s Trust”). On December 21, 2012, all notes issued to the Family Trust were assigned to the Survivor’s Trust (the “WS Trust Notes”) which in turn assigned certain promissory notes, in the aggregate principal amount of $500,000, to Lisa Liebman. The WS Trust Notes accrue interest at rates ranging between 3.25% and 12.0% per annum. The principal on the WS Trust Notes is payable on demand and interest is payable on a quarterly basis.
  
An aggregate of 2,423,965 warrants to purchase shares of the Company’s common stock were either issued to or subsequently assigned to the Survivor’s Trust, at exercise prices ranging between $1.00 and $3.38 per share, as additional consideration for entering into the loan agreements. The Company recorded debt discount in the amount of $2,091,538 as the estimated value of the warrants. The debt discount was amortized as non-cash interest expense over the term of the debt using the effective interest method. The debt discount had been fully amortized as of December 31, 2012. Thus, during the three months ended March 31, 2013 and 2014, no interest expense was recorded from the debt discount amortization.
  
During the three months ended March 31, 2014 and 2013, the Company incurred interest expense of $22,136 and $46,623, respectively, on the WS Trust Notes. At March 31, 2014 and 2013, there wasn’t any accrued interest on the WS Trust Notes.

 

17
 
  

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

(b)Between January 2011 and December 2012, Kim Giffoni the Company’s Executive Vice President of Foreign Sales and Investor Relations, greater than 10% shareholder and a director, loaned $300,000 to the Company. As consideration for the loans, the Company issued promissory notes in the aggregate principal amount of $300,000 (the “Giffoni Notes”). The Giffoni Notes accrue interest at rates ranging between 3.25% and 6.0% per annum. The principal and interest on the Giffoni Notes is payable over the next three months with bi-weekly payments of $10,000. During the three months ended March 31, 2014 and 2013, the Company incurred interest expense of $685 and $3,355, respectively, on the Giffoni Notes. At March 31, 2014, and 2013, accrued interest on the Giffoni Notes totaled nil and $17,330, respectively.
  
(c)On December 21, 2012 the William Shell Survivor’s Trust assigned certain promissory notes, in the aggregate principal amount of $500,000, to Lisa Liebman (the “Liebman Notes”), a related party. Lisa Liebman is married to Dr. Shell. The Liebman Notes accrue interest at rates ranging between 3.25% and 3.95% per annum. The principal and interest on the Liebman Notes is payable on demand. During both the three months ended March 31, 2014, and 2013, the Company incurred interest expense on the Liebman Notes of $4,732. At March 31, 2014, and 2013, accrued interest on the Liebman Notes totaled $4,632 and $26,686, respectively.
  
(d)On June 28, 2013, the Company and CMFG entered into four contemporaneous agreements and thus are considered one arrangement. The components of the agreements are detailed as follows:

 

Workers’ Compensation Receivables Funding, Assignment and Security Agreement, as amended – The Company has assigned the future proceeds of accounts receivable of WC benefit claims with dates of service between the year 2007 and December 31, 2012 (the “Funded Receivables”), to CMFG. In exchange, the Company received a loan of $3.2 million. Until such time as CMFG has been repaid the entire $3.2 million, the monthly division of collections on Funded Receivables will be distributed as follows: First, to CMFG as a servicing fee in an amount equal to five percent (5%) of the collections; Second, to CMFG to pay off any shortfalls from previous months (a shortfall will have been deemed to occur if CMFG receives less than $175,000 in a given month); Third, to CMFG in an amount up to $175,000; Fourth, to the Company in an amount of $125,000; Fifth, to CMFG and the Company, the remainder of the Funded Receivables split at a ratio of 50% to 50%. Once CMFG has received payment of $3.2 million in collections from Funded Receivables, the Funded Receivables will cease to be distributed as described above, and will instead be distributed as follows: First, to CMFG as a servicing fee in an amount equal to five percent (5%) of the collections; and Second, to CMFG and the Company, the remainder of the Funded Receivables split at a ratio of 45% to 55%, respectively.
   
Common Stock Warrant to James Giordano, CEO of CMFG – The Company issued a ten (10) year warrant to purchase 1,412,500 shares of common stock at an exercise price of $2.00 per share (the “Giordano Warrant”) as consideration for consulting services performed by Mr. Giordano, as described below. The warrants became exercisable during December 2013. The exercisable amount is limited to the average trading volume for the ten days prior to the date of exercise.
   
Professional Services and Consulting Agreement with Mr. Giordano – The Company entered into a consulting arrangement with Mr. Giordano for consulting services relating to medical receivable billing, billing/management strategies, and areas related to financing. Mr. Giordano’s only form of compensation for his consulting services was the issuance of the Giordano Warrant. The consulting agreement terminates at such time as all the obligations or contemplated transactions detailed in the Giordano Warrant have been satisfied.
   
Professional Services and Consulting Agreement with CMFG – The Company entered into a consulting arrangement with CMFG for consulting services relating to medical receivable billing, billing/management strategies, and areas related to financing. The agreement provided for the Company to pay a one-time fee of $64,000 upon execution of the agreement.

 

On June 28, 2013, CMFG funded $750,000, net of an escrow amount of $123,047 and loan origination fees in the amount of $41,250. On October 1, 2013, simultaneous with an assignment of the Workers’ Compensation Receivables Funding, Assignment and Security Agreement, dated June 27, 2013, as amended by a First Amendment, dated as of September 30, 2013, by CMFG to Raven Asset-Based Opportunity Fund I LP, a Delaware limited partnership (“Raven”), the Company received the balance due from the Funded Receivables agreement. The Company received cash of $2,449,897, net of fees and a release of the escrow funds of $123,047.

 

18
 
 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

As additional consideration, Raven received a warrant to purchase 400,000 shares of the Company’s common stock at an exercise price of $2.00 per share (the “Raven Warrant”)(See Note 5). The warrants are exercisable April 1, 2014. However, the exercisable amount is limited to the average trading volume for the ten days prior to the date of exercise. The Company accounted for the additional issuance of warrants as a modification of the original award issued June 28, 2013.

 

The Company recorded debt discount in the amount of $925,521 based on the estimated fair value of the Giordano and Raven Warrants. The debt discount will be amortized as non-cash interest expense over the term of the debt using the effective interest method. During the three months ended March 31, 2014, interest expense of $115,690 was recorded from the debt discount amortization.

 

8. RELATED PARTY TRANSACTIONS

 

Notes Payable

 

As of March 31, 2014, and December 31, 2013, the Company has notes payable agreements issued to related parties with aggregate outstanding principal balances of $2,466,887 and $2,621,067, respectively (See Note 7).

 

9. EQUITY TRANSACTIONS

 

On March 21, 2014, the Company entered into a subscription agreement with Ultera Pty Ltd ATF MPS Superannuation Fund (“Ultera”). Dr. Wenkart, a director of the Company, is the owner and director of Ultera. The Company issued and sold to Ultera 400,000 shares of its common stock. The issuance resulted in aggregate gross proceeds to the Company of $240,000.

 

During March 2014, the Company issued an aggregate of 281,666 shares of its common stock pursuant to agreements with its directors and consultants to the Company. The shares were valued at an average of $0.77 per share based on the fair market value of the common stock on the date of issuance. As a result of these issuances, the Company recorded a reduction in its liabilities of $176,500 and a prepaid asset of $39,300. The prepaid asset is being amortized over three months.

 

10. COMMITMENTS AND CONTINGENCIES

  

Income Taxes

 

The Company filed its 2010 federal and state tax returns in April 2011 and June 2011, respectively, without including payment for amounts due. The 2010 federal and state tax returns reflected an amount owed to the IRS and California Franchise Tax Board of approximately $3,600,000 and $1,000,000, respectively. The Company had entered into agreements with the Internal Revenue Service and the California Franchise Tax Board to extend the payment of these taxes over a mutually agreeable period of time. In aggregate, the Company paid $550,000 to the IRS and $350,000 to the California Franchise Tax Board.

 

In June of 2010 the Company filed amended tax returns for 2010 based upon its assessment that for certain sales collectability at the time of the sale could not be reasonably assured, therefore, these sales did not meet the criteria of a sale for tax purposes. The IRS commenced an audit of the Company’s 2010 amended tax return in November 2012. In March 2014 the IRS completed its examination. The IRS did not accept the Company’s assertion that certain sales did not meet the criteria of a sale for tax purposes, however; in part as a result of the utilization of NOL’s generated during 2011 and 2012, the IRS concluded that the Company’s aggregate tax liability for tax years 2010 through 2012 was only $26,000. In February 2013, the FTB notified the Company by letter that it would take no action on our amended California return until the IRS completed its examination. As a result of the completion of the IRS examination the Company initiated discussions with the FTB. Based upon preliminary communication with the FTB, the Company believes that the FTB will accept the conclusion of the IRS. However, there can be no assurances that the FTB will accept the conclusion of the IRS. If an initial adverse ruling were to occur, we would pursue the arbitration and appeal processes available to us under California tax regulations. If the ultimate disposition is unfavorable to the Company, we would likely not be in a position to pay the outstanding liabilities and could incur additional income tax liabilities for tax years subsequent to 2010.

 

19
 

TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — Unaudited (Continued)

 

Although it is likely that the FTB will arrive at the same conclusion as the IRS, we cannot predict the outcome of the FTB examination. If our position is rejected we would owe approximately $650,000 plus additional interest and penalties and would likely incur liabilities for income taxes in subsequent years. As of March 31, 2014, we have recorded $900,863 in prepaid federal and state income taxes on our balance sheet. As a result of the successful conclusion of the IRS examination, the Company expects to receive a refund from the IRS of approximately $550,000. If the outcome of the FTB examination is favorable to the Company then we anticipate a refund of the remaining prepaid taxes. If not, then prepaid state taxes would be removed from our balance sheet.

 

Leases

 

The Company leases its operating facility under a lease agreement expiring February 28, 2015 at the rate of $13,900 per month and several smaller storage spaces on a month-to-month basis. The Company, as lessee, is required to pay for all insurance, repairs and maintenance and any increases in real property taxes over the lease period on the operating facility.

 

Legal Proceedings

 

The Company is a party to various legal proceedings. At present, the Company believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends. However, legal proceedings are subject to inherent uncertainties, and unfavorable rulings or other events could occur. Unfavorable resolutions could include substantial monetary damages. Were unfavorable resolutions to occur, the possibility exists for a material adverse impact on our business, results of operations, financial position, and overall trends. Management might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. However, the Company has not reached this conclusion with respect to any particular matter at this time.

 

11. SUBSEQUENT EVENTS

 

The Company has evaluated events that occurred subsequent to March 31, 2014 and through the date the financial statements were available to be issued. Management concluded that no additional subsequent events required disclosure in these financial statements other than those disclosed in these notes to these financial statements.

 

20
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report contains forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Such forward-looking statements include statements regarding, among others, (a) our expectations about possible business combinations, (b) our growth strategies, (c) our future financing plans, and (d) our anticipated needs for working capital. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “approximate,” “estimate,” “believe,” “intend,” “plan,” “budget,” “could,” “forecast,” “might,” “predict,” “shall” or “project,” or the negative of these words or other variations on these words or comparable terminology. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found in this Quarterly Report.

 

These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes for the fiscal year ended December 31, 2013, contained in the Company’s Annual Report on Form 10-K dated March 31, 2014.

 

Forward-looking statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements as a result of various factors, including, without limitation, the risks outlined under “Risk Factors”, changes in local, regional, national or global political, economic, business, competitive, market (supply and demand) and regulatory conditions and the following:

 

  Adverse economic conditions;
     
  inability to raise sufficient additional capital to operate our business;
     
  the commercial success and market acceptance of any of our products;
     
  the potential impact of our agreement with CMFG;
     
  the maintenance of our products in the FDA National Drug Code database;
     
  the timing and outcome of clinical studies;
     
  the outcome of potential future regulatory actions, including inspections from the FDA;
     
  unexpected regulatory changes, including unanticipated changes to workers compensation state laws and/or regulations;
     
  the expectation that we will be able to maintain adequate inventories of our commercial products;
     
  the results of our internal research and development efforts;
     
  the adequacy of our intellectual property protections and expiration dates on our patents and products;
     
  the inability to attract and retain qualified senior management and technical personnel; the potential impact, if any, of the Patient Protection and Affordable Care Act of 2010 and the Health Care and Education Reconciliation Act of 2010 on our business;
     
  our plans to develop other product candidates; and
     
  other specific risks referred to in the section entitled “Risk Factors”.

 

We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. All forward-looking statements speak only as of the date of this Quarterly Report. We undertake no obligation to update any forward-looking statements or other information contained herein.

 

Information regarding market and industry statistics contained in this Quarterly Report is included based on information available to us that we believe is accurate. It is generally based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. Except as required by U.S. federal securities laws, we have no obligation to update forward-looking information to reflect actual results or changes in assumptions or other factors that could affect those statements. See the section entitled “Risk Factors” for a more detailed discussion of risks and uncertainties that may have an impact on our future results.

 

21
 

 

Recent Developments

 

We filed amended tax returns for 2010 in June of 2012. We understood that filing such returns would likely result in tax audits on the part of both the IRS and FTB. The IRS commenced an audit of the Company’s 2010 income tax return in November 2012. In March 2014 the IRS completed its examination. The IRS did not accept the Company’s assertion that certain sales did not meet the criteria of a sale for tax purposes, however; in part as a result of the utilization of NOL’s generated during 2011 and 2012, the IRS concluded that the Company’s aggregate tax liability for tax years 2010 through 2012 was only $26,000. As of March 31, 2014, we have recorded $900,863 in prepaid federal and state income taxes on our balance sheet. As a result of the successful conclusion of the IRS examination, the Company expects to receive a refund from the IRS of approximately $550,000.

 

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013

 

 TARGETED MEDICAL PHARMA, INC. AND SUBSIDIARY

Consolidated Statements of Operations (Unaudited)

 For the Three Months Ended March 31, 2014 and 2013

 

       % of       % of 
   2014   Sales   2013   Sales 
                 
Total revenue  $1,800,903    100.0%  $2,811,131    100.0%
Total cost of sales   559,534    31.0%   898,674    32.0%
Gross profit   1,241,369    69.0%   1,912,457    68.0%
Total operating expenses   1,952,155    108.5%   2,420,718    86.1%
Loss from operations   (710,786)   (39.5%)   (508,261)   (18.1%)
Total other expenses   (263,684)   (14.6%)   (1,539)   (0.0%)
Loss before income taxes   (974,470)   (54.1%)   (509,800)   (18.1%)
Income tax expense (benefit)           (239,523)   (8.5%)
NET LOSS  $(974,470)   (54.1%)  $(270,277)   (9.6%)

 

Revenue

 

During the three months ended March 31, 2014 and 2013, the Company recognized total revenue of $1,800,903 and $2,811,131, respectively. Total revenue included product revenues from the Company’s TMP segment and service revenues from the Company’s CCPI segment. Total revenues were comprised as follows:

 

   Three Months Ended March 31,
   2014   % of
total
revenue
   2013   % of
total
revenue
 
Total product revenue  $1,633,280    90.7%  $2,479,551    88.2%
Total service revenue   167,623    9.3%   331,580    11.8%
Total revenue  $1,800,903    100.0%  $2,811,131    100.0%

 

22
 

 

Product sales are invoiced upon shipment at AWP under six models, as described in Note 3 to our consolidated financial statements: Physician Direct Sales, Distributor Direct Sales, Physician Managed, Hybrid, CMFG #1 and CMFG #2 Models (collectively, the “Cambridge Models”). Due to substantial uncertainties as to the timing and collectability of revenues derived from our Physician Managed, Hybrid and CMFG #2 Models, which can take in excess of five years to collect, we have determined that these revenues do not meet the criteria for recognition, in accordance with ASC 605, upon shipment. These revenues are recorded when collectability is reasonably assured, which the Company has determined is when the payment is received, regardless of the year originally invoiced (the “Cash Method”).  Conversely, product sales under the Company’s Physician Direct Sales, Distributor Direct Sales and CMFG #1 Models are recognized upon shipment (the “Accrual Method”). As a result, the Company’s basis of recognizing revenue is a hybrid of the cash and accrual methods.

 

The Company recognized product revenue for the three months ended March 31, 2014 and 2013, of $1,633,280 and $2,479,551, respectively. The distribution of product revenue between the Cash Method and the Accrual Method of revenue recognition is as follows:

 

   Three Months Ended March 31,
Revenue recognition method   2014    % of product revenue     2013    % of product revenue  
Cash method  $667,855    40.9%  $1,446,835    58.4%
Accrual method   965,425    59.1%   1,032,716    41.6%
Total product revenue  $1,633,280    100.0%  $2,479,551    100.0%

 

The decrease in total product revenue is attributed to a decrease in cash collections from the Company’s cash method customers. The decrease in cash collections is attributed to routine fluctuations in payer reimbuisements which are expected to normalize on an annual basis. In addition to product revenue, which is recognized in the TMP segment, the Company also recognizes service revenue from billing and collection services in its CCPI segment. The Company recognized service revenue for the three months ended March 31, 2014 and 2013, of $167,623 and $331,580, respectively. In each of the Physician Managed, Hybrid, and CMFG #2 Models, CCPI provides billing and collection services. In consideration for its services, CCPI receives a service fee that is based upon a percentage of gross collections. Because fees are only earned by CCPI upon collection of the claim, and the fee is not determinable until the amount of the collection of the claim is known, CCPI recognizes revenue at the time claims are paid. Under the CMFG #1 Model (under which CCPI also provides billing and collection services) CCPI recognizes revenue upon receipt of the 23% advance payment from CMFG. The decrease in service revenue of $163,957 (from $331,580 for the three months ended March 31, 2013 to $167,623 for the three months ended March 31, 2014) is attributed to an overall decrease in aggregate collections.

 

Cost of Product Sold

 

The reported cost of product sold for the three months ended March 31, 2014 decreased $212,160 to $139,319 from $351,479 for the three months ended March 31, 2013. The cost of product sold as a percentage of reported product revenue decreased to 8.5% for the three months ended March 31, 2014, compared to 14.2% for the three months ended March 31, 2013. Since the Company recognizes the cost of product sold on all products shipped, regardless of whether the sale resulted from a Cash Method or an Accrual Method customer, the cost of product sold as a percent of product billings (shipments) is more relevant for comparison purposes.

 

The actual cost of product sold as a percent of product billings during the three months ended March 31, 2014, was 7.3% compared with 9.8% in the three months ended March 31, 2013. The decrease in product cost as a percent of product billings is attributed to one time charges that the Company recorded during the three months ended March 31, 2013 as a result of unusable product inventory.

 

23
 

 

The following table illustrates the timing impact of the Company’s revenue recognition policy on cost of product sold:

 

   Three Months Ended March 31, 
   2014   2013 
Derived from Consolidated Statements of Operations:          
Reported product revenue  $1,633,280   $2,479,551 
Cost of product sold  $139,319   $351,479 
           
Cost of product sold as a % of reported revenue   8.5%   14.2%
           
Derived from Actual Billings (net of rapid pay discounts):          
Cash method billings  $937,928   $2,556,177 
Accrual method billings   965,425    1,032,716 
Total actual billings  $1,903,353   $3,588,893 
Cost of product sold  $139,319   $351,479 
           
Cost of product sold as a % of actual billings   7.3%   9.8%

 

Cost of Services Sold

 

The cost of services sold for the three months ended March 31, 2014, decreased $126,980 to $420,215 from $547,195 for the three months ended March 31, 2013. Cost of services sold consists primarily of salaries and employee benefits and fees paid to third parties assisting in the collection of outstanding receivables, both of which experienced a significant decrease. During the three months ended March 31, 2014 and 2013, salaries and employee benefits were $346,505 and $417,629, respectively, a decrease of $71,124. The decrease in salaries and employee benefits was the result of a 10% reduction in personnel at the Company’s billing and collections subsidiary. The remaining difference is primarily attributed to the $35,840 decrease in fees paid to third party collection services. During the three months ended March 31, 2013, the Company paid to a third party service a fee equal to 15% of gross collections resulting from their efforts. However, during the three months ended March 31, 2014, the amount paid to a third party service was only 5% of gross collections.

 

Operating Expenses

 

Operating expenses for the three months ended March 31, 2014, decreased $468,563 to $1,952,155 from $2,420,718 for the three months ended March 31, 2013. Operating expenses as a percentage of total revenue increased from 86% of revenue to 108% of revenue in part due to reduced revenue from the Company’s Cash Method customers. Operating expenses consist of research and development expense (which increased $26,403), and selling, general and administrative expenses (which decreased $494,966). Changes in these items are further described below.

 

Research and Development Expense

 

Research and development expenses for the three months ended March 31, 2014 increased $26,403, to $58,483 from $32,080 for the three months ended March 31, 2013. The level of expense varies from year to year depending on the number of clinical trials that we have in progress. During the three months ended March 31, 2014, a clinical study with the University of Cincinnati Physicians Company, LLC, an Ohio nonprofit, limited liability company, was being conducted on the effects of Theramine in the prevention of migraine headaches. The financial obligations attributed to this clinical study were the primary cause of the increase in research and development expenses during the three months ended March 31, 2014.

 

24
 

 

Selling, General and Administrative Expense

 

Selling, general and administrative expenses (“SG&A”) were $1,893,672 and $2,388,638 for the three months ended March 31, 2014 and 2013, respectively. As reflected in the table below, the decrease in SG&A for the three months ended March 31, 2014, when compared to the three months ended March 31, 2013, was primarily the result of various fluctuations in the following expense categories: salaries and employee benefits, professional fees, insurance and general and administrative expenses.

 

   Three Months Ended March 31,
   2014   2013   $ Change   % Change 
                 
Salaries and employee benefits  $1,131,675   $1,534,402   $(402,727)   (26.2%)
Professional fees   461,365    286,788    174,577    60.9%
Rent   71,357    60,302    11,055    18.3%
Insurance   60,176    92,260    (32,084)   (34.8%)
Depreciation & amortization   55,624    49,416    6,208    12.6%
General and administrative   113,475    365,470    (251,995)   (69.0%)
Total selling, general and administrative expenses  $1,893,672   $2,388,638   $(494,966)   (20.7%)

 

The $402,727 decrease in salaries and employee benefits is primarily attributed to a reduction in stock based compensation expense of $278,727 and sales commissions of $80,417.

 

During the three months ended March 31, 2014 and 2013, the Company recorded $12,451 and $291,178, respectively, related to the grants of stock options and restricted stock awards to our employees and non-employee directors. The decrease in stock based compensation is due to the timing of stock option grants. During the three months ended March 31, 2013, the Company granted options to purchase approximately 600,000 shares of the Company’s common stock, the majority of which were immediately exercisable. Conversely, no options were granted during the three months ended March 31, 2014. Excluding the decrease of $278,727 ($291,178 - $12,451) from stock based compensation, salaries and employee benefits decreased by $124,000.

 

The Company rewards key sales personnel through a combination of a base salary and commissions. During the three months ended March 31, 2014 and 2013, the Company incurred commissions, which are primarily tied to revenue, of $71,126 and $151,543, respectively, a decrease of $80,417. The decrease in commissions is primarily attributed to the 36% decrease in total revenue.

 

The second largest component of our SG&A is professional fees. During the three months ended March 31, 2014, the Company experienced an increase in professional fees primarily as a result of service fees paid to increase investor and consumer awareness about the Company. During the three months ended March 31, 2014 and 2013, these service fees equaled $122,000 and nil, respectively. The Company also experienced an increase in audit related fees of $20,101, in part caused from changing our independent auditors. The remaining increase in professional fees is due to various types of professional fees, none of which are significant individually.

 

Insurance expense decreased by $32,084 during the three months ended March 31, 2014 compared to the three months ended March 31, 2013. The decrease is primarily related to a decrease in premiums associated with the Company’s Directors and Officers insurance policy. During January 2014 the Company changed its insurance company and modified the coverage amounts of its Directors and Officers insurance policy. As a result of these changes the annual premium decreased by approximately $140,000.

 

Property and equipment are stated at cost and are depreciated using the straight line method over the estimated useful lives of the assets, which generally range between 3 and 7 years. During the three months ended March 31, 2014, depreciation and amortization remained relatively unchanged. The slight increase in depreciation and amortization of $6,208 is attributed to the timing of when assets were placed in service.

 

25
 

 

General and administrative expense experienced a decrease of $251,995 during the three months ended March 31, 2014 over the three months ended March 31, 2013. During the three months ended March 31, 2014, the Company experienced an overall decrease in revenue as a result of decreased cash collections on its outstanding receivables. As such, an effort was made to either postpone or eliminate discretionary expenses. Travel and office related expenses, components of the Company’s general and administrative expenses, represented some of the largest individual decreases. The remaining decreases in general and administrative expenses are a combination of several types of expenses, none of which are significant individually.

 

Other Income and Expenses

 

Other income and expense includes interest expense, amortization of discounts on notes payable and changes in the fair value of the Company’s warrant derivative liability. During the three months ended March 31, 2014, the Company reported other expense of $263,684 compared with an expense of $1,539 during the three months ended March 31, 2013.

 

Interest expense increased by $169,682, resulting in interest expense of $259,200 in the three months ended March 31, 2014, as compared to an expense of $89,518 in the three months ended March 31, 2013. The increase was primarily due to the $3.2 million loan with Cambridge Medical Funding Group (the “Cambridge Note”) that was completed on October 1, 2013. During the three months ended March 31, 2014, the Company incurred interest expense from the Cambridge Note of $98,970 and recorded non-cash interest expense of $115,690 based on the estimated fair value of the warrants issued in connection with the Cambridge Note. The $214,660 increase in interest expense attributed to the Cambridge Note was partially offset by a reduction in interest expense on notes payable to related parties of $33,186.

 

Changes in the fair value of the Company’s warrant derivative liability resulted in expense of $4,484 in the three months ended March 31, 2014, compared with income of $87,979 in the three months ended March 31, 2013. In July 2012 the Company issued 1,158,981 warrants with anti-dilution ratcheting provisions. At March 31, 2014 and 2013, only 95,000 of these warrants were outstanding. The expense in the three months ended March 31, 2014, represents an increase in the warrant derivative liability. Conversely, during the three months ended March 31, 2013, income was recognized due to a decrease in the warrant derivative liability in connection with the remaining 95,000 warrants.

 

Current and Deferred Income Taxes

 

The Company filed its 2010 federal and state tax returns in April 2011 and June 2011, respectively, without including payment for amounts due and has not made estimated tax payments for the 2011 and 2012 tax years. The Company had entered into agreements with the Internal Revenue Service and the California Franchise Tax Board to extend the payment of these taxes over a mutually agreeable period of time. In aggregate, we have paid $550,000 to the IRS and $350,000 to the California Franchise Tax Board. Our 2010 federal and state tax returns reflected an amount owed to the IRS and California Franchise Tax Board of approximately $3,600,000 and $1,000,000, respectively. We were unable to pay the remaining installment payments.

 

As a result of our assessment that for certain sales’ collectability at the time of the sale could not be reasonably assured, these sales did not meet the criteria of a sale for tax purposes. The Company recalculated its 2010 and 2011 tax liabilities and determined that no income taxes are owed for either year. We filed amended tax returns for 2010 in June of 2012 and in September 2012 filed our 2011 returns using a change in accounting method consistent with our financial results restatement. We understood that filing such returns would likely result in tax audits on the part of both agencies. The IRS commenced its audit in November 2012. In March 2014 the IRS completed its examination. The IRS did not accept the Company’s assertion that certain sales did not meet the criteria of a sale for tax purposes, however; in part as a result of the utilization of NOL’s generated during 2011 and 2012, the IRS concluded that the Company’s aggregate tax liability for tax years 2010 through 2012 was only $26,000. In February 2013, the FTB notified the Company by letter that it would take no action on our amended California return until the IRS completed its examination. As a result of the completion of the IRS examination the Company initiated discussions with the FTB. There can be no assurances that the FTB will accept the conclusion of the IRS and will not pursue collection and enforcement efforts.

 

26
 

 

We recorded an income tax benefit in the three months ended March 31, 2013 of $239,523. However, in June 2013 the Company made a decision to fully reserve its net deferred tax assets. As such, the Company did not record an income tax benefit during the three months ended March 31, 2014.

 

The ultimate realization of deferred tax assets is dependent upon the existence, or generation, of taxable income in the periods when those temporary differences and net operating loss carryovers are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in carryover years, projected future taxable income, available tax planning strategies, and other factors in making this assessment. Based on available evidence, management believes it is less likely than not that all of the deferred tax assets will be realized. Accordingly, the Company has established a 100% valuation allowance of $7,682,867.

 

Net Loss

 

Net loss for the three months ended March 31, 2014, was $974,470 compared to a net loss of $270,277 for the three months ended March 31, 2013. The increased net loss was a result of a combination of decreased revenues, decreased expenses and the absence of an income tax benefit as described above.

 

FINANCIAL CONDITION

 

Our negative working capital of $9,411,772 as of March 31, 2014 increased $780,667 from our December 31, 2013 negative working capital of $8,631,105. Our operating losses during the three months ended March 31, 2014 were funded primarily by proceeds from the sale of our common stock of $240,000. 

 

Unrecognized Accounts Receivable

 

As of March 31, 2014, we have approximately $8.0 million in unrecognized accounts receivable and unrecognized revenues that potentially will be recorded as revenue in the future as our CCPI subsidiary secures claims payments on behalf of our Cash Method customers. Except for collection expenses incurred by CCPI, all expenses associated with these unrecognized accounts receivable, including cost of products sold, have already been expensed in our financial statements. In addition, for federal and state income tax purposes the Company has recognized these unrecognized accounts receivable as revenues. Therefore, the Company will not incur current tax liabilities for these unrecognized accounts receivable when they are collected.

 

For the three months ended March 31, 2014, the Company performed its regular analysis of outstanding invoices comprising unrecognized accounts receivables; specifically, the underlying outstanding insurance claims for each physician customer which is the source of future payment of these outstanding invoices. The analysis takes into account the value of claims outstanding, the age of these claims, and historical claims settlement and payment patterns. At March 31, 2014, the Company determined that collections on its unrecognized accounts receivable would approximate $8.0 million. The analysis also took into account the impact of the agreements with CMFG, particularly the agreement dated June 28, 2013, as amended, regarding future collections. In exchange for loans of $3.2 million the Company assigned its interest in certain pre-2013 workers compensation claims to CMFG and agreed to share approximately 50% of future collections proceeds from settlement of such claims. At March 31, 2014, cumulative payments made to CMFG pursuant to the CMFG #2 Model were $914,285. The Company allocated these payments as debt repayment of $700,815 and interest expense of $213,470. Thus, at March 31, 2014, the remaining principal amount due to CMFG was $2,499,185. The Company expects CMFG will receive aggregate future payments of approximately $3.7 million. As a result of this updated and expanded analysis, of the total amount of $8.0 million in unrecognized accounts receivable, the Company expects to retain approximately $4.3 million, net of estimated amounts of future proceeds belonging to CMFG pursuant to CMFG #2.

 

27
 

 

LIQUIDITY AND CAPITAL RESOURCES

 

We have historically financed operations through cash flows from operations as well as equity transactions and related party loans. As noted above, we entered into an agreement with CMFG that provided for loans of $3.2 million. Due to the uncertainty of our ability to meet our current operating and capital expenses, in their report on our audited annual financial statements as of and for the years ended December 31, 2013 and 2012, our independent auditors included an explanatory paragraph regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that led to this disclosure by our independent auditors. There is substantial doubt about our ability to continue as a going concern as the continuation and expansion of our business is dependent upon either obtaining future equity financings or achieving profitable operations in order to repay the existing short-term debt and to provide a sufficient source of operating capital. No assurances can be made that the Company will be successful in obtaining equity financing needed to continue to fund its operations, or that the Company will achieve profitable operations and positive cash flow. Our inability to take these actions as and when necessary would materially adversely affect our liquidity, results of operations and financial condition.

 

The Company filed its 2010 federal and state tax returns in April 2011 and June 2011, respectively, without including payment for amounts due. The 2010 federal and state tax returns reflected an amount owed to the IRS and California Franchise Tax Board of approximately $3,600,000 and $1,000,000, respectively. The Company had entered into agreements with the Internal Revenue Service and the California Franchise Tax Board to extend the payment of these taxes over a mutually agreeable period of time. In aggregate, the Company paid $550,000 to the IRS and $350,000 to the California Franchise Tax Board.

 

In June of 2010 the Company filed amended tax returns for 2010 based upon its assessment that for certain sales collectability at the time of the sale could not be reasonably assured, therefore, these sales did not meet the criteria of a sale for tax purposes. The IRS commenced an audit of the Company’s 2010 amended tax return in November 2012. In March 2014 the IRS completed its examination. The IRS did not accept the Company’s assertion that certain sales did not meet the criteria of a sale for tax purposes, however; in part as a result of the utilization of NOL’s generated during 2011 and 2012, the IRS concluded that the Company’s aggregate tax liability for tax years 2010 through 2012 was only $26,000. In February 2013, the FTB notified the Company by letter that it would take no action on our amended California return until the IRS completed its examination. As a result of the completion of the IRS examination the Company initiated discussions with the FTB. There can be no assurances that the FTB will accept the conclusion of the IRS and will not pursue collection and enforcement efforts. If an initial adverse ruling were to occur, we would pursue the arbitration and appeal processes available to us under California tax regulations. If the ultimate disposition is unfavorable to the Company, we would likely not be in a position to pay the outstanding liabilities and could incur additional income tax liabilities for tax years subsequent to 2010.

 

Although it is likely that the FTB will arrive at the same conclusion as the IRS, we cannot predict the outcome of the FTB examination. If our position is rejected we would owe approximately $650,000 plus additional interest and penalties and would likely incur liabilities for income taxes in subsequent years. As of March 31, 2014, we have recorded $900,863 in prepaid federal and state income taxes on our balance sheet. As a result of the successful conclusion of the IRS examination, the Company expects to receive a refund from the IRS of approximately $550,000. If the outcome of the FTB examination is favorable to the Company then we anticipate a refund of the remaining prepaid taxes. If not, then prepaid state taxes would be removed from our balance sheet.

 

Net cash used in operating activities for the three months ended March 31, 2014, was $76,061 as opposed to net cash provided by operating activities of $24,728 during the three months ended March 31, 2013. Cash used in investing activities for the three months ended March 31, 2014 and 2013, was $880 and $68,395, respectively. During the three months ended March 31, 2014 and 2013, we incurred internal software development costs for our PDRx claims management and collection system of $880 and $57,187, respectively, and purchased property and equipment of nil and $11,208, respectively. Historically, capital expenditures have been financed by cash from operating activities, equity transactions and related party loans.

 

Net proceeds from the sale of common stock of $240,000 combined with existing cash offset the negative cash flows from operating, investing and debt repayment activities and we experienced a decrease in cash and cash equivalents of $399,220 in the three months ended March 31, 2014. A decrease in cash collections on claims filed by CCPI on behalf of customers utilizing the Physician Managed Model and Hybrid Model negatively impacted cash flows in the three months ended March 31, 2014. The collection cycle and cash flows may also be significantly affected if our mix of business can be shifted from longer collection cycle business, such as workers compensation, to markets with shorter collection cycles, such as private insurance and Medicare.

 

28
 

 

OFF-BALANCE SHEET ARRANGEMENTS

 

The Company’s June 28, 2013, agreement with CMFG, as amended, is an off-balance sheet arrangement that could have a material current effect, or that is reasonably likely to have a material future effect, on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures, or capital resources. Under this agreement, certain workers’ compensation claims have been assigned to CMFG in exchange for loans to the Company. In addition to repaying these loans the Company would share future collections with CMFG, and thereby reduce the availability of future income to fund the operations of the Company.

 

CONTRACTUAL OBLIGATIONS

 

The Company leases its operating facility under a lease agreement expiring February 28, 2015 at the rate of $13,900 per month and several smaller storage spaces on a month-to-month basis. The Company, as lessee, is required to pay for all insurance, repairs and maintenance and any increases in real property taxes over the lease period on the operating facility.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a Smaller Reporting Company as defined by Rule 12b-2 of the Exchange Act and in item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures.

 

The Company’s management, including our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of March 31, 2014, and has determined that our disclosure controls and procedures were effective as of March 31, 2014.

 

Limitations on the Effectiveness of Disclosure Controls.

 

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error.  A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls.

 

Changes in Internal Control over Financial Reporting.

 

There have not been any changes in the Company’s internal controls over financial reporting that occurred during the Company’s three months ended March 31, 2014, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

29
 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company is a party to various legal proceedings. At present, the Company believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends. However, legal proceedings are subject to inherent uncertainties, and unfavorable rulings or other events could occur. Unfavorable resolutions could include substantial monetary damages. Were unfavorable resolutions to occur, the possibility exists for a material adverse impact on our business, results of operations, financial position, and overall trends. Management might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. However, the Company has not reached this conclusion with respect to any particular matter at this time.

 

Item 1A. Risk Factors.

 

There have been no material changes from risk factors previously disclosed in Item 1A included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 31, 2014.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

On March 21, 2014, the Company entered into a subscription agreement with Ultera Pty Ltd ATF MPS Superannuation Fund (“Ultera”). Dr. Wenkart, a director of the Company, is the owner and director of Ultera. The Company issued and sold to Ultera 400,000 shares of its common stock. The issuance resulted in aggregate gross proceeds to the Company of $240,000. These shares were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act.

 

During March 2014, the Company issued an aggregate of 281,666 shares of its common stock pursuant to agreements with certain of its directors and consultants to the Company. The shares were valued at an average of $0.77 per share based on the market value of the common stock on the date of issuance. These shares were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

 

Exhibit
Number
  Description
31.1*   Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a)
31.2*   Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a)
32.1*   Certification of Chief Executive Officer and Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code
     
101.INS**   XBRL Instance Document
101.SCH**   XBRL Taxonomy Extension Schema Document
101.CAL**   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**   XBRL Taxonomy Extension Label Linkbase Document
101.PRE**   XBRL Taxonomy Extension Presentation Linkbase Document

 

 

* Filed herewith.

** In accordance with Rule 406T of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

 

30
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TARGETED MEDICAL PHARMA, INC.
     
Date: May 20, 2014 By: /s/ William E. Shell, MD
    William E. Shell, MD
    Chief Executive Officer
     
Date: May 20, 2014 By: /s/ William B. Horne
    William B. Horne
    Chief Financial Officer and
Principal Accounting Officer

 

31
 

 

Exhibit 31.1

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, William E. Shell, MD, as Chief Executive Officer of Targeted Medical Pharma, Inc., certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Targeted Medical Pharma, Inc. for the first quarter ended March 31, 2014;
   
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 20, 2014

 

By: /s/ William E. Shell, MD  
Name: William E. Shell, MD  
Title: Chief Executive Officer  

 

 
 

 

Exhibit 31.2

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, William B. Horne, as Chief Financial Officer of Targeted Medical Pharma, Inc., certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Targeted Medical Pharma, Inc. for the first quarter ended March 31, 2014;
   
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 20, 2014

 

By: /s/ William B. Horne  
Name: William B. Horne  
Title: Chief Financial Officer  

 

 
 

Exhibit 32.1

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report on Form 10-Q of Targeted Medical Pharma, Inc. (the “Company”) for the fiscal quarter ended March 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), William E. Shell, MD, as Chief Executive Officer of the Company, and William B. Horne, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 20, 2014 By: /s/ William E. Shell, MD
    William E. Shell, MD
  Chief Executive Officer
     
Date: May 20, 2014 By: /s/ William B. Horne
    William B. Horne
 

Chief Financial Officer and

Principal Accounting Officer

 

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and is not being “filed” as part of the Form 10-Q or as a separate disclosure document for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act except to the extent that this Exhibit 32.1 is expressly and specifically incorporated by reference in any such filing.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.